University of Ottawa Heart Institute
|University of Ottawa Heart Institute|
|Location||Ottawa, Ontario, Canada|
|Care system||Public Medicare (Canada) (OHIP)|
|Affiliated university||University of Ottawa & The Ottawa Hospital|
|Lists||Hospitals in Canada|
The University of Ottawa Heart Institute (UOHI) is Canada’s largest and foremost cardiovascular health centre. It began as a department in The Ottawa Hospital, and since has evolved into Canada’s only complete cardiac centre, encompassing prevention, diagnosis, treatment, rehabilitation, research, and education.
UOHI cares for more than 80,000 cardiac patients each year, and patient satisfaction is among the highest in Ontario, averaging 98 percent. The Heart Institute is affiliated with The Ottawa Hospital and the University of Ottawa.
The Institute also provides training to more than 100 physicians annually and runs an extensive cardiovascular research program, with 60 principal investigators and research funding of approximately $65 million a year.
UOHI was founded in 1969 by Dr. Wilbert J. Keon, with financial support from the Ontario Ministry of Education. Dr. Keon worked with numerous partners, including all of the hospitals in the region, the University of Ottawa, and the Ottawa Hospital Regional District Planning council, to ensure the vision of a world-renowned Institute would unfold as planned. The first phase of the Heart Institute—the Cardiac Unit, as it was then known—officially opened on May 11, 1976.
UOHI is now the sole, independent provider of specialized cardiovascular care for the Champlain Local Health Integration Network, home to over 1 million people (9 percent of the population of Ontario), and serves more than 40 referral hospitals throughout the province.
In 2004, UOHI recruited Dr. Robert Roberts from Baylor College of Medicine to serve as President and Chief Executive Officer. Dr. Roberts, an internationally recognized investigator in the field of molecular genetics, was brought in to place a greater emphasis on research within the Institute. Shortly afterwards, UOHI established the Ruddy Canadian Cardiovascular Genetics Centre, the first such centre in Canada and one of only a handful worldwide dedicated to cardiovascular genetics.
The Institute has been responsible for numerous ‘firsts,’ including:
- First use of point of care genetic testing in clinical medicine as part of the RAPID GENE study.
- Ontario's first angioplasty
- The first use in Canada, and 11th in the world, of the Jarvik 7 artificial heart as a bridge to transplant
- A heart transplant on the youngest recipient in Canada (an 11-day-old infant)
- Canada's first cardiac positron emission tomography (PET) centre
- Discovery of a genetic mutation that causes one of the most common forms of heart disease—atrial fibrillation
- Identification of the first single nucleotide polymorphism that increases susceptibility to heart disease regardless of other established risk factors
- A one-of-a-kind Canadian home telehealth monitoring program that cuts hospital readmission by 54 percent for heart failure patients
UOHI maintains a clinical staff of over 650, including physicians, nurses, technicians, and other health professionals. In addition to standard care, approximately 100 clinical trials are underway at the Institute at any time.
More than 1,500 open-heart procedures at UOHI each year require anesthesia, including coronary artery bypass, valve replacement, heart transplant, pulmonary thromboendarterectomy, mechanical circulatory assist devices and others. Clinical anesthesia is also provided for a growing number and variety of pacemaker and implantable cardioverter-defibrillator, percutaneous aortic valve, and arrhythmia procedures.
UOHI is a national centre for cardiac imaging. The Institute employs all standard imaging modalities and evaluates experimental techniques and applications. UOHI also has the rare capability to develop and produce novel, short-lived nuclear tracers on site. The on-site cyclotron lets the Institute produce many of its own medical isotopes, particularly for PET imaging. UOHI’s Nuclear Cardiology Program is the largest such clinical program in Canada.
UOHI’s cardiac surgeons perform more than 1,400 open-heart procedures annually, and the Institute is known for its reconstructive heart-valve surgery program. It has among the lowest mortality rates and largest patient volumes in North America, especially for high-risk patients. Surgical specialties include:
- Heart valve repair
- Percutaneous aortic valve replacement
- Multi-vessel small thoracotomy
- Heart transplantation
- Mechanical assist devices
- Thoracoscopic surgical ablation
- Pulmonary thromboendarterectomy
The Heart Institute is the provincial centre for pulmonary thromboendarterectomy.
Cardiac Prevention and Rehabilitation
The Cardiac Prevention and Rehabilitation program focuses its efforts in five areas: cardiac rehabilitation, the Heart Health Education Centre (for patient and public education), the Champlain Cardiovascular Disease Prevention Network, the Ottawa Model for Smoking Cessation (implemented in more than 70 medical institutions across Canada), and behavioral and risk modification research.
Approximately 50,000 patients a year visit UOHI’s cardiology clinics for testing and treatment of heart disorders. The Cardiology program operates a number of specialized clinics that address various conditions and risk factors for heart disease.
The Institute’s cardiologists conduct more than 6,000 cardiac catheterization procedures annually, to identify obstructions in patients’ coronary arteries. Interventional cardiologists also treat coronary artery disease with catheter-based techniques.
The ST-Elevation Myocardial Infarction (STEMI) Protocol, developed at UOHI, specifies that paramedic in Ottawa identify patients with a STEMI heart attack and transport them directly to the Institute. The program has cut mortality rates from heart attack in Ottawa by half.
UOHI’s division of nursing manages or supports programs and units within the Heart Institute, including the cardiac catheterization and electrophysiology labs, the cardiac operating rooms, and the cardiac surgery intensive care unit.
UOHI offers specialized cardiac nursing training and education in a number of areas, such as critical care, provincial programs in cardiac CT, cardiac PET, artificial hearts, and pulmonary thromboendarterectomy.
Since 2004, a concerted effort to grow research funding at UOHI has resulted in a 300 percent increase in total grant awards. The Institute has more than 60 principal investigators and 175 research staff members whose work encompasses all aspects of cardiovascular medicine. Research programs include:
- Atherosclerosis, Genetics & Cell Biology
- Biomaterials and Regeneration
- Biomedical Engineering
- Cardiac Anesthesiology
- Cardiac Imaging
- Cardiac Prevention & Rehabilitation Research
- Cardiac Surgery Research
- Cardiology Research
- Cardiovascular Devices
- Cardiovascular Endocrinology
- Cardiovascular Genetics
- Cardiovascular Research Methods Centre
- Clinical Services Research
- Clinical Trials
Recently, Heart Institute investigators:
- Identified the strongest genetic risk factor for coronary artery disease and heart attack to date (the 9p21 gene)—the first major risk factor discovered since cholesterol
- Discovered the genetic basis for atrial fibrillation, the most common form of cardiac arrhythmia, affecting 250,000 Canadians
- Conducted the most comprehensive assessment of high blood pressure in Canada in 15 years
- Developed a model smoking cessation program that is in use in more than 70 hospitals across Canada and is being adopted internationally
- Unlocked the mechanism controlling a gene that regulates weight loss
- Developed a novel biomaterial that grows new blood vessels
- Developed Canada's first cardiac autopsy guidelines now in use in Ontario
- Developed an integrated city-wide protocol that cuts heart attack deaths by half
Education and Training
UOHI trains physicians, nurses, technologists, technicians, and other health professionals, as well as graduate students and post-doctoral students in the life and biomedical sciences. The Heart Institute also provides continuing education and best practice training for health care professionals and institutions, and develops patient education tools and programs to facilitate and support self-management of cardiovascular risk factors.
The Institute is certified by the Royal College of Physicians and Surgeons of Canada for residency and fellowship training in cardiac surgery, cardiology, and cardiac anesthesiology.
- Gollob MH, Jones DL, Krahn AD, et al. (June 2006). "Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation". The New England Journal of Medicine 354 (25): 2677–88. doi:10.1056/NEJMoa052800. PMID 16790700.
- McPherson R, Pertsemlidis A, Kavaslar N, et al. (June 2007). "A common allele on chromosome 9 associated with coronary heart disease". Science 316 (5830): 1488–91. doi:10.1126/science.1142447. PMC 2711874. PMID 17478681.
- Reid RD, Mullen KA, Slovinec D'Angelo ME, et al. (January 2010). "Smoking cessation for hospitalized smokers: an evaluation of the 'Ottawa Model'". Nicotine & Tobacco Research 12 (1): 11–8. doi:10.1093/ntr/ntp165. PMID 19903737.
- Le May MR, So DY, Dionne R, et al. (January 2008). "A citywide protocol for primary PCI in ST-segment elevation myocardial infarction". The New England Journal of Medicine 358 (3): 231–40. doi:10.1056/NEJMoa073102. PMID 18199862.
- Leenen FH, Dumais J, McInnis NH, et al. (May 2008). "Results of the Ontario survey on the prevalence and control of hypertension". CMAJ 178 (11): 1441–9. doi:10.1503/cmaj.071340. PMC 2374854. PMID 18490640.
- Teng AC, Adamo K, Tesson F, Stewart AF (June 2009). "Functional characterization of a promoter polymorphism that drives ACSL5 gene expression in skeletal muscle and associates with diet-induced weight loss". The FASEB Journal 23 (6): 1705–9. doi:10.1096/fj.08-120998. PMID 19218499.
- Suuronen EJ, Zhang P, Kuraitis D, et al. (May 2009). "An acellular matrix-bound ligand enhances the mobilization, recruitment and therapeutic effects of circulating progenitor cells in a hindlimb ischemia model". The FASEB Journal 23 (5): 1447–58. doi:10.1096/fj.08-111054. PMID 19136616.